Skip to main content
Fig. 6 | Antimicrobial Resistance & Infection Control

Fig. 6

From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

Fig. 6

Incremental cost outcomes per patient for CAZ-AVI sequence vs. meropenem sequence. Abbreviations: CAZ-AVI ceftazidime-avibactam, CAZ-AVI sequence: CAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem.

Meropenem sequence: Meropenem, followed by colistin + tigecycline + high-dose meropenem

Back to article page